Sanofi's Nexviazyme hits primary goal in Pompe disease study
Seeking Alpha ·
Sanofi ( SNY ) said Tuesday that Nexviazyme met its primary endpoint in a phase 3 study of treatment-naïve infants six months of age and younger with infantile-onset Pompe disease, with participants alive and free of invasive ventilation at 52 weeks.
DYAX Investor Sentiment
Bullish (Long) 46% · Bearish (Short) 54%
238 participants
Related News
- Google demands changes to AI copyright laws
- This Gold-Standard Forecaster Predicted 4.2% Inflation Months Before the Fed. Here's What They Think Is Coming Next for U.S. Investors.
- Life Electric unit Rad Life Mobility buys QuietKat
- Is The Deal Between Nvidia and Palantir a Game Changer?
- Winamp Group Announces the Filing of a U.S. Lawsuit Against Suno
- Vishay Intertechnology drops 6%, prices $750M stock at $50 per share